Uterine fibroid embolization (UFE) and hysterectomy are two different procedures used to treat uterine fibroids. While both procedures are effective in treating fibroids, they differ in several ways.
What is Uterine Fibroid Embolization?
UFE is a minimally invasive procedure that involves blocking the blood supply to the uterine fibroids by injecting tiny particles into the uterine arteries that feed them. This causes the fibroids to shrink and die over time. UFE is performed by a radiologist and typically takes 1-2 hours under local anesthesia. Patients may experience some cramping and discomfort after the UFE treatment, but they are usually able to resume their normal activities within a few days. UFE preserves the uterus, making it a good option for women who wish to maintain their fertility.
What is Hysterectomy?
On the other hand, a hysterectomy is a surgical procedure that involves the removal of the entire uterus. This procedure is usually performed under general anesthesia and requires a longer hospital stay and recovery time. Hysterectomy is often recommended for women who have severe symptoms or large fibroids, and who do not wish to maintain their fertility. Hysterectomy is considered a permanent solution to fibroids as it eliminates the possibility of fibroids growing back in the future.
Differences in UFE and Hysterectomy
One of the main advantages of UFE over hysterectomy is that it is a less invasive procedure, which means that it has a shorter recovery time. Additionally, UFE preserves the uterus and may be a better option for women who wish to maintain their fertility. Hysterectomy, on the other hand, is a more invasive procedure that carries a higher risk of complications, such as infection, bleeding, or damage to surrounding organs.
However, there are some cases where a hysterectomy may be the preferred treatment option. For example, if a woman has a large fibroid or multiple fibroids, or if she has other uterine conditions such as endometriosis or adenomyosis, a hysterectomy may be the best option.
Conclusion
In conclusion, both UFE and hysterectomy are effective treatment options for uterine fibroids, but they differ in terms of invasiveness, recovery time, and the ability to preserve fertility. Women who are considering these procedures should discuss their options with their healthcare provider to determine which treatment is right for them based on their individual needs and medical history.
Uterine fibroids are common, non-cancerous tumors of the uterus.
It’s estimated that by the age of 35, 40% of Caucasian women and up to 60% of African American women will have uterine fibroids.
Genetics, race, obesity, and higher estrogen levels are all considered risk factors for developing fibroids.
Uterine Fibroid Market Information By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), By Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2027Market ScenarioMarket Research Future (MRFR) speculates that the U.S. uterine fibroid market is likely to garner USD 39,993.2 million, grabbing a CAGR of 3.24% during the forecast period (2016-2022).
Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2394 Market Potential and PitfallsUterine fibroids are spreading over the entire U.S. at a rapid pace mainly due to the increased prevalence of uterine fibroids in the African-American race.
The U.S. uterine fibroid market is anticipated to touch high growth figures in the long run mainly due to the surging prevalence of uterine fibroids and the rising number of hysterectomy surgeries every year.
Several treatment options available such as pharmacotherapy, self-help techniques, invasive surgical procedures, and uterine artery embolization are propelling the market growth in the U.S.The introduction of minimally invasive surgeries such as myomectomy and hysterectomy for treating the excruciating pain of uterine fibroids is expected to encourage the market growth.
Such surgeries have reduced the chances of infection, reduced the hospital stay, and, lowered the recovery time, thereby contributing to the growth.
This has resulted in limited treatment options for uterine fibroids.
